Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Elucidating tissue and subcellular specificity of the entire SUMO network reveals how stress responses are fine-tuned in a eukaryote.

Science advances·2025

Same author

Redox-regulated Aux/IAA multimerization modulates auxin responses.

Science (New York, N.Y.)·2025

Same author

Implementing a nurse-led prehabilitation program for patients undergoing spinal surgery.

Nursing·2024

Same author

Going Virtual: Adapting an Institutional Annual Bereavement Event During the COVID-19 Pandemic.

The Journal of pediatrics·2023

Same author

Early Bereavement Psychosocial Outcomes in Parents of Children Who Died of Cancer With a Focus on Social Functioning.

JCO oncology practice·2023

Same author

Training in Expression of Authentic Condolences in Healthcare: A Pilot Study.

Journal of palliative medicine·2022

Search research articles

Related Experiment Video

Updated: May 5, 2026

Experimental Approaches to Tissue Engineering

Experimental Approaches to Tissue Engineering

Published on: August 30, 2007

Patent term extensions: issues, challenges and implications for pharmaceuticals.

Lisa Clark¹, Debbie Beadle

¹Griffith Hack IP, Level 10, 161 Collins Street, Melbourne, VIC 3000, Australia.

Pharmaceutical Patent Analyst

|November 19, 2013

Summary

This summary is machine-generated.

Patent terms are often shortened by lengthy drug approval processes. Patent term extensions aim to compensate for this lost time, ensuring fair market exclusivity for pharmaceutical innovations globally.

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Related Experiment Videos

Last Updated: May 5, 2026

Experimental Approaches to Tissue Engineering

Experimental Approaches to Tissue Engineering

Published on: August 30, 2007

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Author Spotlight: Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Area of Science:

Pharmaceutical Science
Intellectual Property Law
Regulatory Affairs

Background:

Standard patent terms are 20 years from filing.
Drug development and regulatory approval frequently exceed 10 years.
This significantly reduces the effective patent exclusivity period for pharmaceuticals.

Purpose of the Study:

To summarize issues, challenges, and implications of patent term extensions.
To analyze the impact of regulatory delays on pharmaceutical patent life.
To explore global approaches to compensating for patent term loss.

Main Methods:

Literature review of patent term extension policies.
Analysis of regulatory approval timelines for pharmaceutical products.
Comparative study of patent extension mechanisms across different countries.

Main Results:

Regulatory delays substantially erode pharmaceutical patent life.
Patent term extensions are implemented in many countries to address this.
Varying approaches and complexities exist in global patent extension systems.

Conclusions:

Patent term extensions are crucial for maintaining pharmaceutical market exclusivity.
Addressing patent term loss is vital for incentivizing drug innovation.
International harmonization of patent extension policies warrants further consideration.